Research Topics
| T VesikariSummaryAffiliation: University of Tampere Country: Finland Publications
| Collaborators
|
Detail Information
Publications
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccineTimo Vesikari
University of Tampere Medical School, Tampere, Finland
N Engl J Med 354:23-33. 2006..The risk of intussusception was similar in vaccine and placebo recipients. (ClinicalTrials.gov number, NCT00090233.)..- Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infantsTimo Vesikari
University of Tampere Medical School, Tampere, Finland
Vaccine 24:4821-9. 2006.... - A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccineTimo Vesikari
University of Tampere, Tampere, Finland
Pediatr Infect Dis J 25:590-5. 2006..No clinically significant illness occurred among children who received vaccine or placebo or in the child to whom the vaccine virus was transmitted... 
Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjectsTimo Vesikari
University of Tampere Medical School, Tampere, Finland
Hum Vaccin Immunother 8:921-8. 2012..Assessment of long-term antibody persistence after priming, and the effects of a one-year booster dose in children and adolescents was needed...- Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infantsTimo Vesikari
Vaccine Research Center, Medical School, University of Tampere, Tampere, Finland
Pediatr Infect Dis J 31:509-13. 2012..Potential impact of breast-feeding on the efficacy and immunogenicity of human rotavirus G1P[8] vaccine was examined in this exploratory analysis... - Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of ageTimo Vesikari
University of Tampere Medical School, Tampere, Finland
Vaccine 30:3082-9. 2012..Dose 1 may be administered at 9 months if early protection is required, but it should be recognised that a second dose is required promptly with a minimum of 3-month interval between doses... - Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderlyTimo Vesikari
Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
Vaccine 30:1388-96. 2012.... - Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvantTimo Vesikari
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
Pediatr Infect Dis J 28:563-71. 2009..Adjuvanted influenza vaccines may offer a solution... - Rotavirus vaccinesTimo Vesikari
University of Tampere, Medical School, Vaccine Research Center, Finland
Scand J Infect Dis 40:691-5. 2008..Both vaccines have now been distributed in millions of doses. Post-marketing data have not shown any gross signal for IS with either vaccine, but further data and analyses are required for final conclusion on safety of these vaccines... - Emerging data on the safety and efficacy of influenza vaccines in childrenTimo Vesikari
University of Tampere Medical School Vaccine Research Center, University of Tampere, Tampere, Finland
Pediatr Infect Dis J 27:S159-61. 2008..This article will focus mainly on the efficacy of live attenuated intranasal influenza vaccine as an option in young children... - European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summaryTimo Vesikari
Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
J Pediatr Gastroenterol Nutr 46:615-8. 2008 - European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in EuropeTimo Vesikari
Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
J Pediatr Gastroenterol Nutr 46:S38-48. 2008 - Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of ageTimo Vesikari
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
Pediatrics 121:e568-73. 2008.... - Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)Timo Vesikari
University of Tampere Medical School, Tampere, Finland
Int J Infect Dis 11:S29-35. 2007.... - Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled studyT Vesikari
Vaccine Research Centre, Medical School, University of Tampere, Tampere, Finland
Lancet 370:1757-63. 2007..We aimed to assess the efficacy of the oral live attenuated human rotavirus vaccine Rotarix (RIX4414) for prevention of rotavirus gastroenteritis in European infants during their first 2 years of life... - Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccineTimo Vesikari
University of Tampere Medical School, Tampere, Finland
Pediatr Infect Dis J 26:632-8. 2007.... - Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 yearsTimo Vesikari
University of Tampere Medical School, Tampere, Finland
Pediatr Infect Dis J 26:153-8. 2007..Given the overlap in MMR and varicella vaccination schedules, development of a combined vaccine appears logical and would facilitate the introduction of 2 doses of varicella vaccination in healthy children with no additional injections... - MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccinationT Vesikari
University of Tampere Medical School, Medical School FM3, 33014 Tampere, Finland
Vaccine 27:6291-5. 2009..Altogether, these data further support the potential use of MF59-adjuvanted influenza vaccine as a safe and highly immunogenic influenza vaccine for young children... - RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in EuropeTimo Vesikari
University of Tampere Medical School, Tampere, Finland
Vaccine 28:345-51. 2009..5% (95% CI, 91.3-96.8%) for up to 2 years after vaccination. There were no statistically significant differences between RotaTeq and placebo for any of the safety outcomes. In Europe, RotaTeq was highly efficacious and well tolerated... - Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trialTimo Vesikari
Vaccine Research Center, University of Tampere, Biokatu 10, Tampere, Finland
J Clin Virol 53:22-8. 2012..Conventional techniques for diagnosing influenza based on viral cell culture or disease serology have limitations, and molecular assays, such as real-time polymerase chain reaction (rtPCR) are increasingly used... - Oil-in-water emulsion adjuvant with influenza vaccine in young childrenTimo Vesikari
University of Tampere Medical School, Tampere, Finland
N Engl J Med 365:1406-16. 2011..The efficacy of inactivated influenza vaccines is known to be poor in infants and young children... - Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of ageTimo Vesikari
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
Pediatr Infect Dis J 30:e130-41. 2011..We evaluated catch-up vaccination schedules with 10-valent pneumococcal nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV)... - Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trialTimo Vesikari
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
Vaccine 29:4274-84. 2011..ACWY-TT can be co-administered with MMRV without affecting immunogenicity or safety profiles of either vaccine. This study has been registered at www.clinicaltrials.gov NCT00474266... - Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infantsT Vesikari
Vaccine Research Center, Medical School, University of Tampere, FIN 33014 Tampere, Finland
Vaccine 29:2079-84. 2011..1-90.8%) and 90.5% (95% CI: 86.2-93.8%). Reactogenicity and safety profiles of the two vaccine formulations were similar. Liquid formulation of the rotavirus vaccine allows greater flexibility in supply and reduces logistical costs... - Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescenceTimo Vesikari
University of Tampere, School of Medicine, Vaccine Research Center, FM3, Biokatu 10, 33520 Tampere, Finland
Pediatrics 126:e762-70. 2010..This study evaluated the immunogenicity, safety, and tolerability of a MF59-adjuvanted H5N1 vaccine in a population 6 months through 17 years of age... 
Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension StudyTimo Vesikari
Vaccine Research Centre, University of Tampere Medical School, Biokatu 10, Tampere, Finland
Eur J Pediatr 169:1379-86. 2010....- Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in EuropeTimo Vesikari
University of Tampere, Medical School, FIN 33014 Tampere, Finland
Vaccine 28:5272-9. 2010..RIX4414 was immunogenic and well tolerated in European infants and the co-administration of routine childhood vaccines with RIX4414 did not negatively impact the immune responses to these vaccines... - Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 monthsTimo Vesikari
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
Pediatr Infect Dis J 29:e47-56. 2010..This study examined the safety, reactogenicity, and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with MMRV vaccine... - An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolTimo Vesikari
Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
Pediatr Infect Dis J 29:314-8. 2010..In this study, we evaluated the immunogenicity and safety of GARDASIL administered concomitantly with REPEVAX (diphtheria, tetanus, acellular pertussis, and poliomyelitis vaccine)... - Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day careTimo Vesikari
Tampere University Medical School FM3, Biokatu 10, 33520 Tampere, Finland
Pediatrics 118:2298-312. 2006.... - Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish childrenTimo Vesikari
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
J Infect Dis 194:370-6. 2006..A corresponding tetravalent (types G1, G2, G3, and G4) reassortant vaccine based on bovine-human (UK) rotavirus reassortant tetravalent (BRV-TV) vaccine was developed concurrently... - Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infantsTimo Vesikari
Vaccine Research Center, University of Tampere Medical School, FIN 33014 Tampere, Finland
Pediatr Infect Dis J 23:937-43. 2004..Rotavirus gastroenteritis, a major cause of mortality and morbidity worldwide, is a vaccine-preventable disease. New safe and effective candidate rotavirus vaccines are needed to replace the withdrawn rhesus rotavirus-based oral vaccine... - Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infantsT Vesikari
Medical School FM3, University of Tampere, 33014, Finland
Vaccine 22:2836-42. 2004..It is concluded that RIX4414 strain HRV vaccine is virtually non-reactogenic and, at high titer, highly immunogenic in susceptible infants... - [Varicella vaccinations for everybody or for selected groups?]Timo Vesikari
Tampereen yliopiston lääketieteen laitos FM3 33014 Tampereen yliopisto
Duodecim 118:81-5. 2002 - Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccineTimo Vesikari
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
Pediatr Infect Dis J 29:957-63. 2010..This study evaluated whether RV5 remained efficacious beyond 2 years... - Clinical trials of rotavirus vaccines in EuropeTimo Vesikari
University of Tampere Medical School, Tampere, Finland
Pediatr Infect Dis J 25:S42-7. 2006..A large scale safety trial, conducted in Latin America plus Finland, indicated no increased risk of intussusception among recipients of Rotarix compared with placebo. The licensure of Rotarix is in process in the European Union... - Neonatal administration of rhesus rotavirus tetravalent vaccineTimo Vesikari
University of Tampere Medical School, Biokatu 10, 33520 Tampere, Finland
Pediatr Infect Dis J 25:118-22. 2006..We hypothesized that giving the first dose of RRV-TV vaccine during the neonatal period might reduce the reactogenicity of RRV-TV vaccine without compromising the utilization of the vaccine... - A short report on highlights of world-wide development of RIX4414: an European experienceT Vesikari
University of Tampere, Medical School/FM3, Vaccine Research Center, University of Tampere, 33014 Tampere, Finland
Vaccine 24:3779. 2006 - Norovirus genotypes in endemic acute gastroenteritis of infants and children in Finland between 1994 and 2007L Puustinen
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
Epidemiol Infect 140:268-75. 2012..b was dominant between 2003 and 2004 (83%). In conclusion, genotypes GII.4 and GIIb have emerged as predominant norovirus genotypes in endemic gastroenteritis affecting young infants and children in Finland... - Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysisX L Pang
Department of Virology, University of Tampere Medical School, Finland
J Clin Virol 13:9-16. 1999..A sensitive method, like reverse transcription polymerase chain reaction (RT-PCR), may reveal more rotaviruses, but the clinical significance of such findings is not well established... - One-step quantitative RT-PCR for the detection of rotavirus in acute gastroenteritisS Q Zeng
Vaccine Research Center, University of Tampere, Medical School, Vaccine Research Center, Biokatu 10, FIN 33520 Tampere, Finland
J Virol Methods 153:238-40. 2008..e. 28% more rotavirus positive cases than identified by EIA. It is concluded that Q-PCR using primers targeted at NSP3 is a rapid and sensitive method for diagnosing acute rotavirus gastroenteritis... - Human caliciviruses in acute gastroenteritis of young children in the communityX L Pang
Department of Virology and Pediatrics, University of Tampere Medical School, Tampere, Finland
J Infect Dis 181:S288-94. 2000..As a group, human caliciviruses are common causative agents of gastroenteritis in children <2 years of age in Finland, and, of these, NLVs cause more severe disease than SLVs... - Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccinesT Vesikari
University of Tampere Medical School, Finland
Acta Paediatr 88:513-20. 1999..However, febrile reactions to RRV-TV rotavirus vaccine are common when the first dose is given at the age of 3 mo... - Effect of rotavirus vaccine on Sapporo virus gastroenteritis in Finnish infantsX L Pang
Department of Virology, University of Tampere, Medical School, Finland
Pediatr Infect Dis J 20:295-300. 2001..SLV disease is characterized by diarrhea, which is usually mild but can be severe. By an unknown mechanism rotavirus vaccine seems to reduce the severity of SLV-associated diarrhea... - Aichi virus infection in children with acute gastroenteritis in FinlandS Kaikkonen
Vaccine Research Centre, University of Tampere Medical School, Biokatu 10, Tampere, Finland
Epidemiol Infect 138:1166-71. 2010..5%), of which four were co-infections with other gastroenteritis viruses. Two Aichi virus genotypes, A and B, were found. Aichi virus appears to be rare in children with acute gastroenteritis in Finland... - Mixed viral infections causing acute gastroenteritis in children in a waterborne outbreakS Räsänen
University of Tampere Medical School, Tampere, Finland
Epidemiol Infect 138:1227-34. 2010..Bloody diarrhoea occurred only when C. jejuni was present. To conclude, massive exposure to several AGE viruses caused mixed infections and severe AGE regardless of the aetiological agents... - Rotavirus vaccines: development and use for the prevention of diarrhoeal diseaseT Vesikari
University of Tampere, School of Medicine, Finland
Ann Med 31:79-85. 1999..Protective efficacy of RRV-TV vaccine in developing countries is lower and a more intensive immunization schedule may be needed. Several other candidate rotavirus vaccines, including bovine-human reassortants, are being investigated... - Prevalence of norovirus GII-4 antibodies in Finnish childrenK Nurminen
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
J Med Virol 83:525-31. 2011..Therefore, protection against NoV infection correlated with strong blocking activity... - Foreword: ESPID/ESPGHAN evidence-based recommendations for rotavirus vaccination in EuropeTimo Vesikari
Tampere, Finland
J Pediatr Gastroenterol Nutr 46:v-vi. 2008 - A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particlesL Huhti
Vaccine Research Center, University of Tampere Medical School, Finland
Arch Virol 155:1855-8. 2010..VLPs were stable for at least 12 months at 4°C, and up to 7 days at ambient temperature. These findings indicate that this method yielded stable and high-quality VLPs... - Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: time trends and geographical variationH Viskari
JDRF Center for Prevention of Type 1 Diabetes in Finland, Finland
Diabetologia 48:1280-7. 2005.... - A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studiesKai Krohn
Institute of Medical Technology, University of Tampere, Biokatu 8, 33520 Tampere, Finland
Microbes Infect 7:1405-13. 2005.... - Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trialPéter Csonka
Department of Pharmacy, University of Tampere School of Public Health and Research Unit, and the Tampere University Hospital, Tampere, Finland
J Pediatr 143:725-30. 2003..Study design Randomized, double-blind, placebo-controlled trial involving 230 children age 6 to 35 months in the emergency department. Each patient received either oral prednisolone (2 mg/kg/d) or placebo for 3 days... - Detection of human coronaviruses in children with acute gastroenteritisMinna Risku
Department of Virology, Medical School, Biokatu 10, FI 33014 University of Tampere, Tampere, Finland
J Clin Virol 48:27-30. 2010..Human coronaviruses (HCoVs) are known respiratory pathogens. Moreover, coronavirus-like particles have been seen by electron microscope in stools, and SARS-HCoV has been isolated from intestinal tissue and detected in stool samples... - Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccineTimo Vesikari
Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
Pediatr Infect Dis J 28:S66-76. 2009..The immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was assessed and compared with the 7-valent pneumococcal conjugate vaccine (7vCRM)... - Rotavirus gastroenteritis in Finnish children in 2006-2008, at the introduction of rotavirus vaccinationSirpa Räsänen
University of Tampere Medical School, Tampere, Finland
Scand J Infect Dis 43:58-63. 2011..RV-associated hospitalizations were seen in children up to the age of 9 y. This study forms the epidemiological background for the follow-up of the impact of universal RV vaccination in Finland introduced in 2009... - Norovirus gastroenteritis in young children receiving human rotavirus vaccineShang Qin Zeng
Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
Scand J Infect Dis 42:540-4. 2010..NVs were the most common etiologic agents of AGE in children under 2 y of age. Human rotavirus vaccine did not protect against NV gastroenteritis... - IL-10 gene polymorphism at -1082 A/G is associated with severe rhinovirus bronchiolitis in infantsMerja Helminen
Paediatric Research Centre, Tampere University and University Hospital, Tampere, Finland
Pediatr Pulmonol 43:391-5. 2008..This finding suggests a different pathogenic mechanism for RSV bronchiolitis as compared with wheezing associated with other viral infections, for example, rhinovirus in infants under 6 months of age... - Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf lifeStan L Block
Kentucky Pediatric Adult Research, Bardstown, Kentucky, USA
Pediatrics 119:11-8. 2007..Rotavirus is the leading cause of dehydrating acute gastroenteritis in infants worldwide. Previous studies of a live pentavalent human-bovine reassortant rotavirus vaccine have shown it to be efficacious across a range of potencies... - Burden of rotavirus disease in European Union countriesMontse Soriano-Gabarro
GlaxoSmithKline Biologicals, Rixensart, Belgium
Pediatr Infect Dis J 25:S7-S11. 2006..With the introduction of new rotavirus vaccines in sight, rotavirus gastroenteritis may be regarded as the single most frequent vaccine-preventable disease among children in the EU... - Live attenuated versus inactivated influenza vaccine in infants and young childrenRobert B Belshe
Saint Louis University Health Sciences Center, St Louis, USA
N Engl J Med 356:685-96. 2007..S. advisory bodies. To evaluate alternative vaccine approaches, we compared the safety and efficacy of intranasally administered live attenuated influenza vaccine with those of inactivated vaccine in infants and young children... - Rotavirus types in Europe and their significance for vaccinationUlrich Desselberger
Cambridge, United Kingdom
Pediatr Infect Dis J 25:S30-41. 2006..A case is made for comprehensive surveillance of cocirculating human rotavirus types in Europe after the implementation of rotavirus vaccination... - A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritisBeatrice De Vos
GlaxoSmithKline Biologicals, Rixensart, Belgium
Pediatr Infect Dis J 23:S179-82. 2004..05) in Latin America. These results show prospects for widespread use of Rotarix to reduce rotavirus disease burden and warrant continued worldwide evaluation... - Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritisGuillermo M Ruiz-Palacios
Instituto Nacional de Ciencas Medicas y Nutricion, , Mexico
N Engl J Med 354:11-22. 2006..ClinicalTrials.gov numbers, NCT00139347 and NCT00263666.).. - Viral etiology and incidence of acute gastroenteritis in young children attending day-care centersVibeke Rosenfeldt
University Clinic of Pediatrics, H S Hvidovre Hospital, Hvidovre, Denmark
Pediatr Infect Dis J 24:962-5. 2005..The purpose of the study was to investigate the frequency, morbidity and cause of acute gastroenteritis in children attending day-care centers in Denmark... - A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusceptionAlbert Z Kapikian
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
J Infect Dis 192:S22-9. 2005..e., ages 3-4 months through age 9 months). In this way, there may be the potential to eliminate or at least significantly decrease the risk of intussusception associated with rotavirus vaccination... - Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centresClare L Hibbert
RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, United Kingdom
Vaccine 25:8010-20. 2007..2%; placebo, 13.4%), vaccination saved US$ 5.47 per child in societal costs. In the high attack-rate season (vaccinated, 4.7%; placebo, 32.1%), vaccination led to a societal costs savings of US$ 144.44 per child... - RotavirusJim Gray
Centre for Infections, Health Protection Agency, London, UK
J Pediatr Gastroenterol Nutr 46:S24-31. 2008 - Options for the prevention of rotavirus disease other than vaccinationJacek Mrukowicz
Polish Institute for Evidence-Based Medicine, Krakow, Poland
J Pediatr Gastroenterol Nutr 46:S32-7. 2008 - A six-fold gradient in the incidence of type 1 diabetes at the eastern border of FinlandAnita Kondrashova
Juvenile Diabetes Research Foundation, Center for Prevention of Type 1 Diabetes, Finland
Ann Med 37:67-72. 2005..This suggests that environmental factors contribute to this steep difference in the incidence rate between these adjacent regions... - JC virus strains indigenous to northeastern Siberians and Canadian Inuits are unique but evolutionally related to those distributed throughout Europe and Mediterranean areasChie Sugimoto
Laboratory of Viral Infection, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
J Mol Evol 55:322-35. 2002..Based on the present findings, we discuss ancient human migrations, accompanied by Type A JCVs, across Asia and to Arctic areas of North America... - Genetic diversity of JC virus in the Saami and the Finns: implications for their population historyHiroshi Ikegaya
Department of Forensic Medicine, University of Turku, Turku, Finland 20520
Am J Phys Anthropol 128:185-93. 2005..These findings are discussed in the context of the population history of the Saami and the Finns. This study provides new complete JCV DNA sequences derived from populations of anthropological interest...